Capitolis Advisors’s GSK GSK Stock Holding History

Capitolis Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,220,000	Closed	-$60.7M	–	424
2021 Q2	$60.7M	Buy	+1,220,000	New	+$58.6M	0.71%	37

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capitolis Advisors's GSK Position: Q3 2021 in Review

Capitolis Advisors sold out of GSK (GSK) in Q3 2021, closing a stake of 1,220,000 shares — an estimated $60.7M sold.

Capitolis Advisors first reported a position in GSK in Q2 2021 and held it in 1 quarter. The position peaked at $60.7M in Q2 2021. 792 funds tracked by Wall St. Rank hold GSK as of Q3 2021.

Capitolis Advisors reported no remaining GSK position as of Q3 2021 after selling out during the quarter.
Capitolis Advisors sold 1,220,000 GSK shares in Q3 2021, an estimated $60.7M.
Capitolis Advisors first reported a position in GSK in Q2 2021 and held it in 1 quarter.
Capitolis Advisors's GSK position peaked at $60.7M in Q2 2021.
792 funds tracked by Wall St. Rank held GSK as of Q3 2021.

Based on Capitolis Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.